The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated non-human primate (NHP) has been described as the most translatable model for experimental reproduction of L-dopa-induced dyskinesia (LID). However, from a drug discovery perspective, the risk associated with investment in this type of model is high due to the time and cost. The 6-hydroxydopamine (6-OHDA) rat dyskinesia model is recommended for testing compounds but relies on onerous, and non-standard behavioral rating scales. We sought to develop a simplified and sensitive method aiming at assessing LID in the rat. The purpose was to validate a reliable tool providing earlier insight into the antidyskinetic potential of compounds in a time/cost-effective manner before further investigation in NHP models.
Introduction
To date, L-dopa is the most effective drug for treating the signs and symptoms of Parkinson's disease (PD) and is still considered the standard therapeutic agent 1, 2 . However, after several years of treatment, L-dopa-induced dyskinesia (LID) occurs in the majority of patients 1, [3] [4] [5] . These highly debilitating motor complications manifest as a variety of abnormal involuntary movements (AIMs), including severe and painful dystonic cramps (sustained abnormal muscle contractions), hyperkinetic and purposeless (choreiform) movements [5] [6] [7] .
The pathophysiological mechanisms underlying LID remain poorly understood despite substantial efforts in research 8, 9 . LID has been proposed to be an aberrant form of neuroplasticity triggered by the combined effects of dopaminergic (DA) denervation and pulsatile stimulation of the DA receptors through repeated L-dopa intake 1, 6 . With increasing duration of treatment, there is an increase in both the frequency and the severity of dyskinesia 6 . Given that L-dopa is still required for the treatment of advanced PD, the management of LID is a crucial challenge 8, 9 . The limited success of anti-dyskinetic drugs in the clinic emphasizes the need to use appropriate animal models with good predictive value. The MPTP-treated non-human primate (NHP) has been described as the most translatable model and the gold standard for experimental reproduction of PD features, as well as dyskinetic syndrome 7, 10, 11 . However, the use of NHPs is costly, time-consuming and raises potential ethical issues. Hence, a drug candidate failing due to lack of efficacy in NHP dyskinesia models may result in losing a significant investment in the research program (potentially resulting in significant consequences for a small biotech company, and in no new drug being available for patients). In agreement with this idea, it has been proposed that early attrition of non-efficacious compounds is crucial for successful central nervous system (CNS) drug development 12, 13 .
To counteract the limitations associated with the use of NHPs in antidyskinetic drug discovery, other simpler models were developed. The unilateral 6-hydroxydopamine (6-OHDA) rat dyskinesia model remains one of the most popular for modeling peak-dose dyskinesia 7 . This model was first described 4 by Cenci and colleagues in 1998 14 and is still widely used and recommended for testing compounds, because it produces a stable and reproducible behavioral outcome 7, 15 . This model relies on a behavioral assessment of LID using a rating scale that includes measurement of locomotor behavior (contralateral turning) as well as abnormal involuntary movements (AIMs), such as forelimb dyskinesia, dystonic posturing of the contralateral side of the body, axial dystonia, manifest as contralateral twisted posture of the neck and upper body, and orolingual dyskinesia, characterized by stereotyped jaw movements and contralateral tongue protrusion 14 . Lundblad and colleagues elegantly demonstrated progressive worsening of AIMs over a 3-week L-dopa treatment using this scoring method 16 . However, the severity of the AIMs was determined based on the frequency of occurrence of different subtypes of behaviors, without taking into account their intensity level, which is known to increase over time along with LID frequency with continued L-dopa treatment in PD patients, as reviewed by Bezard and colleagues 6 . This limitation was later counterbalanced by adding an amplitude score (based on the extent of the movements) in order to differentiate between small but clear forelimb movements and dystonic-like movements involving the whole shoulder 17, 18 .
Another rating scale aimed at further assessing the intensity of LID was meanwhile developed by Steece-Collier and colleagues 19 . Interestingly, in this latter method, the score was assigned not only based on the duration of a behavior, but also on its features, in order to better reflect LID severity 19 .
All of these rating scales have recently been compared in a validation study, in order to assess their reliability and translatability 20 . The authors obtained slight differences in the responses to reference compounds depending on the rating scale, and suggest (as do other authors) a need to standardize the method 7, 20 . Notably, they stated that methods enabling the detection of variations in both duration and intensity of LID resulted in improved sensitivity to the effect of the reference compound amantadine, a non-competitive NMDA receptor antagonist 7 .
In clinical research, it has been highlighted that the development of a single sensitive and robust rating scale was challenging because of the different types of dyskinesias and their different temporal patterns, anatomical distributions and associated disabilities 8 . Similarly, although well 5 validated, the different methods described above reflect a lack of harmonization in the behavioral assessment of LID in animal models. Most of the existing scales are relevant for profound investigations into the neurobiological mechanisms of LID (if not designed specifically for this purpose) and rely on direct visual observation of a large number of fine behavioral parameters. As a consequence, the impact of subjectivity is high (the experimenter may introduce a subjective bias for each behavioral subtype observed, which influences the global LID score), and the use of a particular method can be challenging for an experimenter who was not trained by the laboratory in which the method was developed. This suggests a need to develop an 'easy-to-use' LID scoring scale that could be used in the 6-OHDA rat as a de-risking strategy, to have earlier insight into drug efficacy before carrying out further expensive studies using NHP models of dyskinesia.
In the present study, we sought to develop a new scoring method, adapted from previous rating scales 14, 16, 17, [19] [20] [21] [22] for the assessment of LID in the rat 6-OHDA dyskinesia model. The purpose was to validate a simplified method focusing on a reduced number of behavioral subtypes easily identified in order to lower the impact of subjectivity and provide reliable data concerning the antidyskinetic potential of a compound in a time/cost-effective manner.
RESULTS & DISCUSSION
As shown in Fig. 2a and Fig. 2b , the animals that received a stereotaxic injection of 6-OHDA showed a significant decrease in the number of TH+ cells within the SNc (81.1% cell loss compared to the unlesioned side, t 34 =11.09; p<0.0001). However, 2 rats showed a more partial lesion, of 31% and 44%, respectively (black dots in Fig. 2b) . TH immunostaining performed in 2 sham animals revealed a number of 22,267 and 15,800 TH+ cells in the SNc, respectively, which was similar to the numbers of TH+ cells observed in the unlesioned side of lesioned rats (18,696 on average). Forelimb use asymmetry and akinesia were assessed using the cylinder test and the stepping test, respectively. As 6 shown in Fig. 2c , the percentage of contralateral forelimb paw use was significantly decreased in 6-OHDA-lesioned rats (29.4%) compared to sham rats (48.4%) (p=0.0005). This motor impairment was reversed after treatment with L-dopa (8 mg/kg) co-administered with benserazide (6 mg/kg).
Consistently, the stepping test procedure reflected a similar motor impairment that was alleviated with the same L-dopa treatment (Fig. 2d) . Indeed, while sham rats made an average of 23.8 adjusting steps with their contralateral paw over 3 trials, vehicle-treated lesioned rats made only 4.4 steps (p<0.0001) and L-dopa-treated lesioned rats made 16.8 steps (p<0.0001 compared to vehicle, p=0.0057 compared to sham). Fig. 2e , reveals that apomorphine challenge significantly induced contralateral rotations, especially in 8 rats, for which the challenge induced over 90 turns/45 min.
Based on immunohistochemistry analysis, these rats underwent a dopaminergic lesion causing a TH+ cell loss of over 80% compared to the unlesioned side and were selected for the assessment of Ldopa-induced dyskinesia (apomorphine did not produce contraversive turn in 10 rats including 2 partially lesioned rats represented by black dots in Fig. 2e and Fig. 2b .
Drug-induced dyskinesia is a frequent debilitating complication in PD, associated with physical and social disabilities. For decades, substantial research efforts have been invested into novel therapeutics that could improve patients' quality of life, with limited success. Consistent with the need to develop standardized and cost/time-effective preclinical tools for anti-dyskinetic drug discovery, we provide evidence highlighting the value of a novel 'easy-to-use' reliable method for behavioral assessment of LID in the rat.
The late stage (Phase II, Phase III) attrition rate of CNS drug-candidates is known to be particularly high, mainly due to lack of efficacy (or safety issues) 12, 13, 23, 24 . The successful development of CNS drugs relies on the development of appropriate animal models for efficacy testing in preclinical studies and a new paradigm for drug development that will give early readouts for proof of concept in order to allow attrition to occur much earlier in the process 12, 13 . This challenge applies to PD drug Page 6 of 35   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d m a n u s c r i p t 7 discovery, especially for the development of antidyskinetic drugs 7 . To date, the MPTP-treated NHP is considered the most predictive animal model of LID 7, 10, 11 . Indeed, after chronic treatment with Ldopa, MPTP-treated monkeys develop choreic and dystonic movements that can be scored using clinical rating scales after only modest adaptations 25 . But the cost and time required to implement this type of studies is associated with a risk of losing a significant investment. The 6-OHDA dyskinesia rat model appears to be a good option to provide a first insight into drug efficacy in a time/costeffective manner 11 . This model has been extensively described as valuable for antidyskinetic drug discovery 7, 11, 20 and relies on behavioral scoring of the LID. A recent study sought to validate 3 contemporary AIM scales available in the literature 20 and highlighted the interest of adding a severity parameter to the scoring of AIM frequency. The scoring scale developed in our study attempts to take this crucial parameter into account. Both severity and adjustment coefficients were applied to a set of specific behavioral subtypes that were selected to reflect different levels of severity ( Table 1) . The goal was to provide an overview of the dyskinetic state of each animal rather than a very deep behavioral assessment. However, we designed our scale to reflect as much contrast as possible within the different levels of AIM severity to increase its sensitivity. It is worth noting that such an approach, relying on assigning a severity coefficient depending on the features of the observed behavior has been used in previous validated scales 19 .
The evaluation of the evolution of the LID over the 3-week period of L-dopa treatment revealed a significant time-dependent increase in the LID score from week 0 to week 3 (p=0.0362) (Fig. 3a) . It worth noting that the LID scores correspond to ranked data. Hence, a square transformation was performed in order to ensure normal distribution and apply parametric tests. Fig 3b shows that "increased locomotion with contralateral bias" and "dystonia" were the main AIM components of the global LID score at week 0 and week 3 respectively (score significantly higher compared to other components). Furthermore, Fig 3b illustrates a significant increase of the score for "increased locomotion with grabbing" on weeks 1 and 2 (p=0.0008, p=0.0038) compared to week 0. On week 3, a significant increase of the score for "axial posture" (p=0.0009) and "dystonia" (p=0.0151) was Our data demonstrate that our rating scale was able to distinguish slight behavioral changes, as
shown by the measurement of the time-dependent worsening of LID. Interestingly, we reported a significant increase of the LID score after one week of L-dopa dosing, consistent with a previous report indicating that AIM and LID can occur after the first-ever dose of L-dopa 26 . Furthermore, the analysis of the different behavioral subtypes separately suggests a moderate increase of the most severe AIM components (i.e. dystonic circling, axial posture and dystonia) on weeks 1 and 2
accompanied by a significant augmentation of contralateral turning with grabbing. The two AIM subtypes "axial posture" and "dystonia" were significantly increased on the week 3 post-L-dopa treatment. This further illustrates the capability of our rating scale to highlight a progressive worsening of the dyskinetic state suggesting the sensitivity of the method. Moreover, the sensitivity of our rating scale allowed to show the amantadine-mediated alleviation of AIMs in a dosedependent manner (using a tight dose range). It worth noting that amantadine-mediated alleviation A c c e p t e d m a n u s c r i p t 9 of the global LID score was mainly associated with an improvement of "dystonia" and, in a lesser extent, "axial posture" AIM components with very limited effect on other behavioral subtypes observed in our rating scale. This is in line with previous data reporting amantadine-mediated alleviation of AIM score with no effect of contralateral turning 20 . Consistent with previous reports 20 , our study illustrates the importance of performing assessments at multiple time-points, as we were able to pinpoint the time window corresponding to the optimal effect of amantadine. This is particularly relevant in experiments investigating compounds for which poor pharmacokinetics data are available, as some agents may reduce the severity of the AIM score at a peak time but prolong the temporal course of motor dysfunction, or have a delayed effect 20 .
One of the reasons proposed to explain the limited success of anti-dyskinetic drugs in the clinic is the lack of validated clinical outcome measures that are responsive to treatment despite the validity of multiple dyskinesia rating scales 27 , and it has been pointed out that the development of a single sensitive and robust rating scale was challenging because of the different types of dyskinesias and their different temporal patterns, anatomical distributions and associated disabilities 8 . Furthermore, the clinical assessment of LID is highly subject to the placebo effect 28 . Similarly, in rat models of dyskinesia, various rating scales were developed and validated over the last decades 14, [16] [17] [18] [19] 21 . These methods rely on direct visual observation of a limited number of behavioral subtypes including orolingual/jaw movements (easily impacted by subjectivity) but only taking into account the severity level of AIM through frequency scores 14 or amplitude scores depending on the observation of parameters easily subjectively appreciated (e.g. angle of torsion in moving animal) 18 . Other scales using a simpler method to determine a severity score focus on a large number of various fine subtypes of behavior or on observation of different parts of the animal's body separately (neck, truck, limbs) 19 . While these methods are appropriate for investigating the neurobiological mechanisms of LID their subjectivity remains high: a large number of subjective parameters may increase the chance of experimenter-dependent errors in assessment influencing an animal's global dyskinetic score. Similarly, assessment of very fine behavioral parameters such as orolingual A c c e p t e d m a n u s c r i p t movements or torsion angle in moving rats may introduce a subjective bias, impact the reproducibility and harm to the need of standardization. The reproducibility could only be ensured by significant training provided by the laboratory in which the method was first validated, as well as internal validation in the laboratory where the new research will be carried out. In a recent study comparing different rating scales, the authors suggested a need for standardization of the methods for assessing LID, as they obtained slight differences in the responses to reference compounds depending on the method used 20 . We believe that focusing on a limited number of behavioral subtypes could lower the impact of subjectivity and improve reproducibility while providing a global overview of the dyskinetic state of each animal. In our study, we observed a restricted number of behavioral subtypes to (i) minimize the impact of subjectivity (assuming that, as subjective bias would be applied to a smaller number of behavioral subtypes, there would be a lower impact on the final LID score due to fewer chances to produce "error") and to (ii) obtain an overall view of the dyskinetic state of the animal at a particular time-point. Orolingual AIM were considered as too easily impacted by subjectivity (potentially hardly identified in dyskinetic moving rats) and were not assessed to minimize the risk to introduce a subjective bias. Our data demonstrate that this parameter may not be required to have a first insight into the antidyskinetic potential of a drug. We believe that this type of method could be more easily harmonized between different laboratories and meet expectations for the preclinical assessment of developing compound. Indeed, the purpose of our scale is not to support mechanistic studies aiming at understanding the neurobiological mechanisms of LID, but rather to provide, from a drug discovery perspective, a valuable, time/costeffective outcome. While different subtypes of AIM may be mediated by different neurobiological mechanisms, assessing the effect of a test compound on the "global dyskinetic state" may help as part of a de-risking strategy to support decision-making during drug development (e.g., a go/no-go decision for initiating NHP studies). Our rating scale focuses on a limited number of behavioral subtypes, including non-dyskinetic behavior (contralateral circling) as well as AIMs with dystonic and hyperkinetic features. The behavioral subtypes assessed were associated with severity coefficients in Page 10 of 35   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d m a n u s c r i p t 11 order to reflect the effect of a test compound on the global dyskinetic state of an animal. Our data demonstrate a time-dependent worsening of LID and a dose-dependent alleviation by amantadine, illustrating the sensitivity of this method.
In the present study, we provided data supporting the reliability of our new LID rating scale.
However, as for other scales, the behavioral assessment relies on subjective observation of the animal, which is the main limitation of this type of a tool. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d m a n u s c r i p t decision-making during the drug development process. Indeed, early attrition of inefficacious compounds is thought to be crucial for successful drug development (especially for CNS drugs), hence the need to develop reliable methods that can rapidly provide efficacy data in a cost-effective manner, before moving the compound forward in expensive and time-consuming studies. We believe that the use of our rating scale in the 6-OHDA dyskinesia model can be valuable if integrated in a derisking strategy during the preclinical development of an antidyskinetic agent. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d m a n u s c r i p t 13 brain atlas 42 . 6-OHDA or vehicle was administered at a rate of 0.4 µL/minute. To avoid reflux, the needle was maintained at the injection site for 5 minutes after the injection.
Materials & Methods

Animals
To limit damage to noradrenergic neurons, imipramine (15 mg/kg, i.p.) was administered 15 min before 6-OHDA lesioning 43 .
The 
Drugs
All drugs (Sigma, France) were dissolved in saline, except 6-OHDA, which was dissolved in a saline solution containing 0.02% ascorbic acid.
In the cylinder and stepping tests, L-dopa methyl ester and benserazide were administered at 8 and 6 mg/kg, ip, respectively 45, 46 .
To induce LID, L-dopa methyl ester and benserazide were administered daily (between 9.00 and 10.00 AM) for 3 weeks at 25 and 5 mg/kg, s.c., respectively, starting from the fourth week postsurgery 47, 48 . This dose of L-dopa is the same as typically used in the behavioral sensitization paradigm [49] [50] [51] [52] [53] [54] and this type of sensitized context was associated with LID in PD patients 6 . Amantadine or its vehicle was administered at 20, 30 and 40 mg/kg, i.p., 40 min before L-dopa/benserazide administration 16, 55, 56 . A c c e p t e d m a n u s c r i p t
14
Behavioral procedures Cylinder test
Forelimb use asymmetry was assessed as previously described 57 
Stepping test
Forelimb akinesia was assessed as previously described 58 3 weeks after cerebral injection of 6-OHDA.
Briefly, the experimenter firmly held the rat's hindquarters while it supported its weight on its contralateral forelimb. Then, the experimenter moved the rat forward along the table (0.9 m in 5 seconds) three consecutive times per session. All sessions were video-recorded and the number of adjusting steps was counted afterwards by a blinded investigator. For each session, the total score calculated was the sum of the number of adjusting steps observed for the contralateral paw in the three tests. The sessions took place between 10.30 and 11.30 AM, 3 weeks post-surgery.
L-dopa induced dyskinesia
L-dopa mediated induction of AIMs is only possible in animals with a massive nigral DA lesion 26, 59 .
Thus, the 8 rats displaying a full DA lesion (i.e., over 90 contralateral turns after apomorphine challenge 60,61 ) were included in this procedure. These rats received a daily injection of L-dopa and benserazide for 3 weeks (15 testing sessions), starting the 4th week post-surgery (after the stepping test and cylinder test procedures). Each session was performed between 9.00 and 10.00 AM. Then, 4 additional testing sessions were performed in order to assess the efficacy of amantadine in reversing the LID. Animals received vehicle on day 1, amantadine 40 mg/kg on day 2, amantadine 30 mg/kg on day 3 and amantadine 20 mg/kg on day 4 ( Fig. 1) . Amantadine or its vehicle was administered 40 min before L-dopa/benserazide administration and 1 hour before the animals were placed in the cylinder and video-tracked for 1 hour. Again, the behavior of the animals was videorecorded and LID scoring was performed retrospectively by a blinded experimenter.
Consistent with previous reports that assumed different levels of severity depending on the features of the AIMs 17-19 , we hypothesized that different behaviors reflected different LID intensity levels. We attributed a global severity score to each rat, based on both the frequency and the intensity of the behaviors, in order to reflect gradual levels of AIM severity. The AIMs were classified into 5 subtypes according to their level of severity according to previously published rating scales 14,16-22 (see Table   1 ). The purpose of our approach was to simplify the scoring method and provide a global AIM score reflecting the dyskinetic state of each animal. To this end, we developed a rating scale including both axial dystonia (neck/trunk torsion toward the side contralateral to the lesion) and forelimb dyskinesia (side to side, up to down tapping or circular movement of the right forelimb, "grabbing") within the same assessment grid. For instance, the AIM subtypes "increased locomotion with grabbing" and "axial posture" include both changes in neck/trunk position and grabbing behavior ( Table 1 ). In line with previous scales 14, 16 , contralateral circling (included under the item "increased locomotion with contralateral bias" in Table 1 ) was not considered "dyskinesia," since contralateral turning can be induced by dopaminergic agonists with very low dykinesiogenic potential 16, 62 . This behavior was considered "normal behavior" following L-dopa administration in unilaterally 6-OHDA lesioned rats A c c e p t e d m a n u s c r i p t 16 and, thus, corresponds to the lowest severity score. The purpose was to eventually weight the score if AIMs such as grabbing or others described in Table 1 were observed.
Each rat was observed for 1 min every 10 min, from 20 to 80 min post L-dopa/benserazide administration. For each subtype of behavior (Table 1) , a frequency score between 0 and 3 (with 0 = absent, 1 = occasional: less than 50% of the time, 2 = frequent: more than 50% of the time, 3 = continuous, uninterrupted) was assigned.
These frequency scores were multiplied by a severity coefficient (see Table 1 ) that was determined prior to the behavioral analysis. These severity scores were adapted from previous studies applying 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 A c c e p t e d m a n u s c r i p t factor of magnitude between "increased locomotion with contralateral bias" and "increased locomotion with grabbing" (1 to 2), then a more important difference between "increased locomotion with grabbing" and "dystonic circling" (2 to 8), a mild to slight difference between behaviors in which a pronounced deviation of the body is observed (8, 12 and 20 for "dystonic circling" and "axial posture and "dystonia" respectively) and a substantial factor of magnitude between "increased locomotion with contralateral bias" and "dystonia" (1 to 20).
For animals displaying different subtypes of behaviors during the same observation period, an adjustment coefficient was also applied, as described in Table 1 . This adjustment coefficient aimed to improve the accuracy of the scoring method by taking into account slight behavioral differences. For instance, we assumed that a rat displaying only "dystonia" (see Table 1 ) during the entire minute of observation time was more severely affected than a rat that displayed "dystonia" most of the time but that also displayed "axial posture" and/or other less severe symptoms.
A global severity score taking into account both the frequency and the intensity of the AIMs was obtained for each rat (the detailed calculations and formulae used are available in Supplementary Material 1). The maximum score that could be accumulated per testing session was 420 (maximum score per observation point: 60; number of observation points per session: 7).
Histological analysis
After the last day of LID scoring, the animals were decapitated under pentobarbital anesthesia (200 mg/kg) and the brain was quickly removed at 4°C on fresh ice. The brains were then post-fixed in ice-cold 4% paraformaldehyde over 24h and processed for paraffin embedding before being sectioned (7-µm slices) in the coronal plane. The slides were stained using antibodies against tyrosine hydroxylase (TH) (rabbit 1/5000: Millipore AB152) and the DAKO LSAB and HRP system (DAKO Real, DAKO France). Immunostaining was processed on a Discovery XT ® Platform (Roche Ventana, Tucson, A c c e p t e d m a n u s c r i p t 18 AZ, USA). All slides were scanned at 20x magnification for whole slide imaging using a NanoZoomer 2.0RS scanner (Hamamatsu, Japan) and analyzed using NIS-AR software (Nikon, Japan). 
Data and statistical analysis
Data were analyzed by Student's t-test, one-way ANOVA, repeated measures ANOVA or two-way repeated measures ANOVA depending on the experimental design. Where appropriate, post-hoc analyses were carried out with Tukey's or Dunnett's tests. All reported p-values are two-sided. The normality of the variables was assessed by Shapiro-Wilk test and the homoscedasticity was assessed by Levene's test. When data were not normally distributed, the data were square-transformed.
Results were expressed as means ± SEM.
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